News
Success Stories: B-BIC’s Work With Platelet Biogenesis
WATCH: B-BIC’s Work With Platelet Biogenesis One of B-BIC’s first grant recipients was Jonathan Thon, a researcher based at Brigham and Women’s Hospital. Jonathan and his team had been researching two technologies necessary for producing platelets outside of the body. They had achieved promising results that demonstrated a microfluidic platform could simulate bone marrow physiological…
Read MoreFAST PITCH FOR FUNDING: What we are looking for when awarding B-BIC partnerships
Potential for commercialization. Technology that addresses an unmet clinical need. Heart, Lung, Blood or Sleep indications. Preliminary data indicating promise of commercialization. Differentiation from competitors. IP filings, with institutions as the assignee. OUR NEXT FAST PITCH FOR FUNDING is Wednesday, January 30, 2019 from 10am – 12pm at NORTHEASTERN UNIVERSITY, 360 Huntington Ave, McLeod Suites, in the…
Read MoreFAST PITCH FOR FUNDING: Quick Tips for a successful pitch
Keep pitch short and focused on the technology and its commercial application. Limit the discussion of preliminary results, and focus on the most relevant results with conclusions – not data. Present the science within the context of the business strategy. OUR NEXT FAST PITCH FOR FUNDING is Wednesday, January 30, 2019 from 10am – 12pm at NORTHEASTERN UNIVERSITY,…
Read MoreNEW AWARD: CONGRATULATIONS DR J. BRIAN MCALVIN
RECIPIENT: Dr. J. Brian McAlvin TITLE: A Novel Method To Treat The Systemic Inflammatory Response Syndrome (SIRS) TYPE OF AWARD: Pilot TECHNOLOGY TYPE: Therapeutic Device CLINICAL AREA: Blood INSTITUTION: Boston Children’s Hospital DESCRIPTION: We have developed highly-selective blood-filtering devices that are capable of filtering of individual, harmful molecules from the blood of patients rendered critically ill by the…
Read MoreTips & Tricks: Explaining Your Proposed Solution
Understand the population you are targeting and why. It may be preferable to define a narrower niche for your entry to the market. Consider where your device/drug will be administered and by what means. This choice will greatly influence the preclinical and clinical development needs and strategies. Most investors will want to see proof-of-concept (POC)…
Read MoreNEW AWARD: CONGRATULATIONS, DR. SYLVIE BRETON!
RECIPIENT: Dr. Sylvie Breton TITLE: Predicting and Preventing Acute Kidney Injury Associated with Cardiovascular Diseases TYPE OF AWARD: PILOT TECHNOLOGY TYPE: Small Molecule Drug CLINICAL AREA: Heart INDICATION: Acute Kidney Injury INSTITUTION: MGH DESCRIPTION: Acute kidney injury (AKI) is a frequent complication of hospitalized patients. Unfortunately, there is no cure for this potentially deadly condition. Thus, a critical…
Read MoreNIH Centers for Accelerated Innovations Program: principles, practices, successes and challenges
Commercializing innovations in academic environments is notoriously challenging. Here, we describe the progress of the NIH Centers for Accelerated Innovations program — initiated in 2013 to address these challenges — which we believe could help set a new standard for the early-stage commercialization of biomedical innovations in academic environments. Read More On Nature.com.
Read MoreB-BIC Partner Update: PLATELET BIOGENESIS RAISES A $10 MILLION SERIES A FINANCING LED BY QIMING US HEALTHCARE FUND
BOSTON, Mass. (June 8, 2017) – Platelet BioGenesis, a biotech startup developing a process to produce life-saving human platelets from stem cells for therapeutic applications, announced it has successfully raised $10 million in Series A financing. The round was led by Qiming US Healthcare Fund and included Vivo Capital, VI Ventures, Adena Partners, eCoast Angels,…
Read MoreTips & Tricks: Customer Research Basics
The “build it and they will come” approach may have worked for Steven Jobs at Apple but does not work for most new products. For us mere mortals, it is important to conduct customer research before proceeding too far with a new idea. You want to know if there is a market for your product…
Read MoreSpecialist Series: What is a “Venture Syndicate” ?
By Jay Knowles An investor syndicate generally consists of three of four investors who have the funds to take the company from idea stage through to clinical proof of concept. Investors may not put all of the investment in upfront (so that they have a little more control over the flow of funds), and they…
Read More